Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor.

Literature DB >> 745020

Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor.

J Mendlewicz, M B Youdim.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 1978 PMID： 745020 DOI： 10.1007/bf01246965

Source DB: PubMed Journal: J Neural Transm Impact factor: 3.575

× No keyword cloud information.

16 in total

Review 1. Multiple forms of monoamine oxidase: fact and artefact.

Authors: M D Houslay; K F Tipton
Journal: Life Sci Date: 1976-08-15 Impact factor: 5.037

2. HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS.

Authors: B BLACKWELL
Journal: Lancet Date: 1963-10-26 Impact factor: 79.321

3. Sequential comparison of L-tryptophan with E.C.T. in severe depression.

Authors: B J Carroll; R M Mowbray; B Davies
Journal: Lancet Date: 1970-05-09 Impact factor: 79.321

4. Dopamine is a monoamine oxidase B substrate in man.

Authors: V Glover; M Sandler; F Owen; G J Riley
Journal: Nature Date: 1977-01-06 Impact factor: 49.962

5. Monoamine-oxidase inhibitors and prolactin secretion.

Authors: J Mendlewicz; M B Youdim
Journal: Lancet Date: 1977-09-03 Impact factor: 79.321

6. Diagnostic criteria for use in psychiatric research.

Authors: J P Feighner; E Robins; S B Guze; R A Woodruff; G Winokur; R Munoz
Journal: Arch Gen Psychiatry Date: 1972-01

7. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.

Authors: J D Elsworth; V Glover; G P Reynolds; M Sandler; A J Lees; P Phuapradit; K M Shaw; G M Stern; P Kumar
Journal: Psychopharmacology (Berl) Date: 1978-04-14 Impact factor: 4.530

8. Amine precursors and depression.

Authors: J Mendels; J L Stinnett; D Burns; A Frazer
Journal: Arch Gen Psychiatry Date: 1975-01

9. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

Authors: W Birkmayer; P Riederer; L Ambrozi; M B Youdim
Journal: Lancet Date: 1977-02-26 Impact factor: 79.321

10. Deprenyl in Parkinson's disease.

Authors: A J Lees; K M Shaw; L J Kohout; G M Stern; J D Elsworth; M Sandler; M B Youdim
Journal: Lancet Date: 1977-10-15 Impact factor: 79.321

10 in total

1. L-deprenyl plus L-phenylalanine in the treatment of depression.

Authors: W Birkmayer; P Riederer; W Linauer; J Knoll
Journal: J Neural Transm Date: 1984 Impact factor: 3.575

2. Is monoamine oxidase inhibitor induced myoclonus serotoninergically mediated?

Authors: J J Askenasy; M D Yahr
Journal: J Neural Transm Date: 1988 Impact factor: 3.575

Review 3. Dopamine and depression.

Authors: A S Brown; S Gershon
Journal: J Neural Transm Gen Sect Date: 1993

8. Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?

Authors: N Mendis; C M Pare; M Sandler; V Glover; G M Stern
Journal: Psychopharmacology (Berl) Date: 1981 Impact factor: 4.530

Review 9. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.

Authors: Moussa B H Youdim
Journal: J Neural Transm (Vienna) Date: 2018-10-19 Impact factor: 3.575

10. MAO-inhibitors in Parkinson's Disease.

Authors: Peter Riederer; Gerd Laux
Journal: Exp Neurobiol Date: 2011-03-31 Impact factor: 3.261